Professor Jo Ki-ki from the Department of Urology at Hanyang University Hospital presented the main results of the CheckMate-9ER study, a phase 3 study of Cabometyx and nivolumab, and the latest foreign guidelines for renal cell carcinoma.
Ipsen Korea announced on October 3 that it will hold an event to share the latest insights into the treatment of renal cell cancer in commemoration of the 5th anniversary of nationwide coverage of Cabometyx (ingredient name: cabozantinib).
This event, chaired by Professor Park Jae-young of Korea University Ansan Hospital, was followed by a presentation on “Optimal Treatment and Cabometics for Renal Cell Carcinoma” by Professor Cho Jeong-gi of Hanyang University Hospital , followed by Professor Seung-hwan Lee of Severance Hospital, Professor Chan-ho Lee of Busan Paik Hospital and Chae-rin Song of Asan Medical Center in Seoul. Professor Jeong Jae-wook of Chilgok Kyungpook National University Hospital attended the expert discussion and shared opinions and clinical experiences on Cabometyx’ treatment of renal cell carcinoma.
Professor Cho Jeong-gi of Hanyang University Hospital introduced the latest updates to foreign guidelines for renal cell carcinoma and then presented the main results of the CheckMate-9ER study, a phase 3 study of Cabometyx and nivolumab. In March 2022, the combination therapy of Cabometyx and nivolumab was approved by the Ministry of Food and Drug Safety as a first-line treatment for patients with advanced renal cell carcinoma.
According to the results of the CheckMate 9ER clinical trial, the median progression-free survival (PFS) of the group treated with the combination therapy Cabometyx and nivolumab was 16.6 months, doubling the 8.3 months of the Sunitinib group.
The Cabometyx + Nivolumab group significantly reduced the risk of disease progression and death by 49% compared with the sunitinib group (hazard ratio for disease progression or death, 0.51; 95% CI, 0.41 to 0. 64; P<0.001). ) The objective response The ORR rate was also 57.7% in the Cabometyx+nivolumab treatment group, or approximately double the 27.1% in the sunitinib treatment group (P<0.001).
Furthermore, in terms of quality of life assessment, patients in the Cabometyx+nivolumab group showed better quality of life than those in the sunitinib group at all time points up to week 91.
Professor Cho then underlined that it is important to increase the overall survival rate by using drugs suited to the patient’s characteristics right from the start. According to the results of METEOR clinical subgroup analysis, a phase 3 clinical trial, in patients with bone metastases, the median PFS was 7.4 months, HR=0.33 (95% CI 0.21–0.5 51) and overall survival (OS) was 20.1 months. , HR=0.54 (95% CI, 0.34–0.84), demonstrating the effect of Cabometyx on bone metastases as a single treatment for secondary or higher renal cell carcinoma.
Furthermore, the results of the CheckMate-9ER subanalysis showed that in patients with bone metastases, the median PFS was 18 months, HR=0.38 (95% CI 0.25–0.59); in patients with liver metastases, median PFS was 11 months, HR = 0.51 (95% CI 0.33–0.79); In case of 2 or more multiorgan metastases, the median PFS was 15 months, HR=0.53 (95% CI 0.43–0.67), underlining that the combination of Cabometyx and nivolumab was effective as a treatment for first line in patients with metastases.
In the subsequent expert debate, the combined therapy of tyrosine kinase inhibitors and checkpoint inhibitors in the treatment of renal cell carcinoma and the trend towards the use of Cabometics in the treatment of renal cell carcinoma at home and abroad were heatedly discussed. ‘abroad. In today’s discussion the experts agreed that since renal cell carcinoma is a disease with frequent relapses and difficult early diagnosis, it is very important to create a therapeutic environment in which effective drugs can be used as early as possible.
Audrey Schweitzer, CEO of Ibsen Korea, said, “Today was an opportunity to reaffirm the clinical value of Cabometyx in the renal cell cancer treatment environment through sharing real-world clinical cases.” She added: “We will continue to expand Cabometyx’s capabilities globally.” “Based on the clinical results, we will continue to collaborate with the medical community and the Korean government to improve the level of treatment of renal cell cancer and improve access to innovation for patients,” she added.
#Ipsen #Korea #Holds #Event #Commemorate #5th #Anniversary #Cabomatics #Salary
